PLENARY SESSION 08: TREATMENT HIGH RISK
Despoina Dimitriou(Democritus University of Thrace), Ιoannis Kotsianidis(Democritus University of Thrace), Elli Papaemmanuil, Elsa Bernard(Inserm), Menelaos Papoutselis(Democritus University of Thrace), George Vrachiolias(Democritus University of Thrace), Paul Costeas(Deakin University), Panagiotis Liakopoulos(Democritus University of Thrace), Athanasios Tasis(Democritus University of Thrace), Christina Misidou(Democritus University of Thrace), Konstantinos Liapis(Democritus University of Thrace), Christina Maria Rimpa(Democritus University of Thrace), Petros Kolovos(Democritus University of Thrace), Ioannis Mitroulis(Democritus University of Thrace), Chryssa Kymbaridou(Democritus University of Thrace), Theodoros Spyropoulos(Democritus University of Thrace), Eleftheria Lamprianidou(Democritus University of Thrace)
Cited by 0
Related Papers
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
|Nature Genetics|2020|739
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
|Nature Medicine|2020|633
Molecular and functional characterization of the Salmonella invasion gene invA: homology of InvA to members of a new protein family
|Journal of Bacteriology|1992|586